[HTML][HTML] The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism

K Abeyama, DM Stern, Y Ito… - The Journal of …, 2005 - Am Soc Clin Investig
K Abeyama, DM Stern, Y Ito, K Kawahara, Y Yoshimoto, M Tanaka, T Uchimura, N Ida…
The Journal of clinical investigation, 2005Am Soc Clin Investig
Thrombomodulin (TM) is an endothelial anticoagulant cofactor that promotes thrombin-
mediated formation of activated protein C (APC). We have found that the N-terminal lectin-
like domain (D1) of TM has unique antiinflammatory properties. TM, via D1, binds high-
mobility group-B1 DNA-binding protein (HMGB1), a factor closely associated with necrotic
cell damage following its release from the nucleus, thereby preventing in vitro leukocyte
activation, in vivo UV irradiation–induced cutaneous inflammation, and in vivo …
Thrombomodulin (TM) is an endothelial anticoagulant cofactor that promotes thrombin-mediated formation of activated protein C (APC). We have found that the N-terminal lectin-like domain (D1) of TM has unique antiinflammatory properties. TM, via D1, binds high-mobility group-B1 DNA-binding protein (HMGB1), a factor closely associated with necrotic cell damage following its release from the nucleus, thereby preventing in vitro leukocyte activation, in vivo UV irradiation–induced cutaneous inflammation, and in vivo lipopolysaccharide-induced lethality. Our data also demonstrate antiinflammatory properties of a peptide spanning D1 of TM and suggest its therapeutic potential. These findings highlight a novel mechanism, i.e., sequestration of mediators, through which an endothelial cofactor, TM, suppresses inflammation quite distinctly from its anticoagulant cofactor activity, thereby preventing the interaction of these mediators with cell surface receptors on effector cells in the vasculature.
The Journal of Clinical Investigation